Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. ETON
ETON logo

ETON Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Eton Pharmaceuticals Inc (ETON) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Buy
Latest Price
24.430
1 Day change
-9.42%
52 Week Range
27.290
Analysis Updated At
2026/04/10
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Eton Pharmaceuticals (ETON) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available for investment. The company's strong revenue growth, bullish analyst ratings, and long-term growth projections make it an attractive option. Despite a slightly overbought technical indicator, the overall outlook supports a buy decision.

Technical Analysis

The technical indicators for ETON are bullish. The MACD is positive and expanding, indicating upward momentum. The RSI is at 84.728, signaling an overbought condition, but this is not uncommon in strong upward trends. Moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). The stock price is currently above key resistance levels (R1: 26.623, R2: 27.758), suggesting continued strength.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
5
Buy
6

Positive Catalysts

  • Strong Q4 performance with an 82.72% YoY revenue increase.

  • Bullish forward guidance with FY26 revenue expected to exceed $110M and long-term targets of $500M by

  • Analyst upgrades with price targets raised to $31, $35, and $52, all maintaining Buy ratings.

  • Expansion of the addressable market through acquisitions like Hemangeol and Desmoda.

Neutral/Negative Catalysts

  • RSI indicates overbought conditions, which could lead to short-term pullbacks.

  • Net income dropped significantly (-347.99% YoY), which might concern some investors despite positive revenue growth.

Financial Performance

In 2025/Q4, Eton Pharmaceuticals achieved an 82.72% YoY revenue increase to $21.28M, showing strong growth. However, net income dropped by -347.99% YoY to $1.48M, reflecting increased costs. EPS improved significantly to -0.17, up 750% YoY, and gross margin increased to 61.56%, up 10.72% YoY, indicating operational improvements.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

Analysts are highly bullish on ETON. Multiple firms, including B. Riley, Craig-Hallum, and H.C. Wainwright, have raised price targets to $31, $35, and $52, respectively, while maintaining Buy ratings. Analysts highlight strong Q4 performance, bullish forward guidance, and long-term growth potential driven by new launches, acquisitions, and operational maturity.

Wall Street analysts forecast ETON stock price to rise
3 Analyst Rating
Wall Street analysts forecast ETON stock price to rise
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 24.430
sliders
Low
26
Averages
30
High
35
Current: 24.430
sliders
Low
26
Averages
30
High
35
B. Riley
Buy
maintain
$26 -> $31
AI Analysis
2026-03-20
Reason
B. Riley
Price Target
$26 -> $31
AI Analysis
2026-03-20
maintain
Buy
Reason
B. Riley raised the firm's price target on Eton Pharmaceuticals to $31 from $26 and keeps a Buy rating on the shares. Following a strong Q4, Eton delivered enhanced revenue visibility with FY26 guidance above $110M and more than 30% adjusted EBITDA margin, alongside long-term targets of a $200M run-rate exiting 4Q27, 50% margins by 2028, and $500M revenue by 2030, reinforcing a multi-year growth trajectory, the analyst tells investors in a research note.
Craig-Hallum
Craig-Hallum
Buy
maintain
$30 -> $35
2026-03-20
Reason
Craig-Hallum
Craig-Hallum
Price Target
$30 -> $35
2026-03-20
maintain
Buy
Reason
Craig-Hallum raised the firm's price target on Eton Pharmaceuticals to $35 from $30 and keeps a Buy rating on the shares following the company's comprehensive Q4 update, which included a top-line beat of $21.3M vs. $20.0M, but was highlighted by bullish forward guidance and long-term targets. Management guided 2026 revenue above consensus at over $110M vs. $105.3M and introduced EBITDA margin guidance of at least 30%, implying about $33M, with differences vs the firm's prior $39M largely explained by FDA program fees and higher R&D.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for ETON
Unlock Now

People Also Watch